2013 Fireside Chats

  • Recommend
  • Tweet
  • Print
  • Email

Fireside chats feature candid discussions between biopharma CEOs and Wall Street analysts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013.

Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation
Monday, February 11, 2013, 8:00am - 8:45am
Moderator: Joel Sendek, Managing Director, Stifel Nicolaus
View the webcast here.

John C. Lechleiter, PhD, Chairman, President and CEO, Eli Lilly
Monday, February 11, 2013, 1:00pm - 1:45pm
Moderator: Mark Schoenebaum, MD, Senior Managing Director and Head, Healthcare Research, ISI Group

N. Anthony Coles, MD, Chairman & CEO, Onyx Pharmaceuticals
Tuesday, February, 12, 2013 , 7:45am - 8:25am
Moderator: Steve Usdin, Senior Editor, BioCentury
View the webcast here.

John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
Tuesday, February, 12, 2013 , 11:00am - 11:25am
Moderator: Joel Sendek, Managing Director, Stifel Nicolaus
View the webcast here.

Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin
Tuesday, February, 12, 2013 , 3:30pm - 3:55pm
Moderator: Salveen Richter, Managing Director, Biotechnology Equity Research, Canaccord Genuity
View the webcast here.

 

Jean-Jacques Bienaimé
Chief Executive Officer, BioMarin

Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $4.5 billion in the summer of 2012. BioMarin 2012 revenues are anticipated to be approximately $500 million. BioMarin is a fully integrated biopharmaceutical company with over 1000 employees.

Prior to joining BioMarin, Mr. Bienaimé served as chairman, chief executive officer, and president of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Under his leadership, Genencor's revenues increased substantially to over $400 million and shareholder value increased dramatically, culminating in the sale of the company to Danisco in the spring of 2005 for an enterprise value of over $1.2 billion.

From 1998 to late 2002, Mr. Bienaimé served as chairman, chief executive officer and president of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corporation. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of senior vice president of worldwide marketing and business development responsible for, among other things, the launch of Lovenox® (for the prevention of pulmonary embolism and treatment of unstable angina) in the United States and Taxotere® (for breast and lung cancer) worldwide. Earlier in his career, he worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.

Mr. Bienaimé is a member of the board of directors of InterMune, Inc., a member of the board of directors of Portola Pharmaceuticals Inc., and a member of the board of directors for Biotechnology Industry Organization (BIO). He received an MBA from the Wharton School at the University of Pennsylvania and a degree in economics from the Ecole Superieure de Commerce de Paris.

N. Anthony Coles, MD
Chairman & CEO, Onyx Pharmaceuticals


Dr. Coles joined Onyx in March 2008 as President and Chief Executive Officer. In 2012, Dr. Coles was appointed as Chairman of the board of directors. Prior to joining Onyx, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb Company, including Senior Vice President of Strategy and Policy; Senior Vice President of Marketing and Medical Affairs, Neuroscience/Infectious Diseases/Dermatology; Vice President, Western Area Sales Cardiovascular and Metabolic Business Unit for U.S. Primary Care; and Vice President, Cardiovascular Global Marketing. From 1992 until 1996, Dr. Coles also held a number of positions of increasing responsibility at Merck & Co., Inc., including Vice President of the Hypertension and Heart Failure Business Group

Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master’s degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a trustee and member of the Executive Committee for the Johns Hopkins University Board of Trustees, as well as a member of the board of trustees for Johns Hopkins Medicine. Dr. Coles is also a member of the board of directors for Laboratory Corporation of America (LabCorp), as well as Campus Crest Communities, Inc., both NYSE traded companies. He is also a member of the board of the Biotechnology Industry Organization (BIO).

Robert Hugin
Chairman and Chief Executive Officer, Celgene Corporation

Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease.

He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. He serves as Chairman-Elect of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of The Darden Foundation, University of Virginia. He also serves on the Board of Trustees of Princeton University as well as a founding Board member of Choose NJ.

Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period. Bob and his wife Kathy have three children and live in Summit, New Jersey.

John C. Lechleiter, PhD
Chairman, President and CEO, Eli Lilly

John C. Lechleiter, Ph.D., has served as president and chief executive officer of Eli Lilly and Company since April 1, 2008.  He became chairman of the board of directors on January 1, 2009.

Lechleiter joined Lilly in 1979 as a senior organic chemist in process research and development and became head of that department in 1982.  In 1984, he began serving as director of pharmaceutical product development for the Lilly Research Centre Limited in Windlesham, England.

He returned to the United States in 1986 as manager of research and development projects for Europe.  In 1988, he became director of development projects management, and he assumed additional responsibility for pharmaceutical regulatory affairs the following year.  In 1991, Lechleiter was named executive director of pharmaceutical product development, and he became vice president in 1993.  He was appointed vice president of regulatory affairs in 1994, was named vice president for development and regulatory affairs in 1996, and became senior vice president of pharmaceutical products in 1998.

In 2001, Lechleiter was appointed executive vice president for pharmaceutical products and corporate development.  In 2004, he became Lilly’s executive vice president for pharmaceutical operations.  And in 2005, he was named president and chief operating officer and joined the board of directors.

Lechleiter received a bachelor of science degree in chemistry from Xavier University (Cincinnati, Ohio) in 1975.  He subsequently studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he received his master’s and doctorate degrees in 1980.  Lechleiter has received honorary doctorates from Marian University (Indianapolis, Indiana), the University of Indianapolis, and the National University of Ireland. 

Lechleiter is a member of the American Chemical Society and Business Roundtable. Dr. Lechleiter serves as chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), as president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and on the boards of United Way Worldwide, Xavier University (Cincinnati, Ohio), the Life Sciences Foundation, and the Central Indiana Corporate Partnership. He also serves on the board of Nike, Inc.

John F. Milligan, PhD
President and Chief Operating Officer, Gilead Sciences

Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.

Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University.

Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.

 

Salveen Richter

Managing Director, Biotechnology Equity Research, Canaccord Genuity

Salveen Richter joined Canaccord Genuity, through the acquisition of Collins Stewart LLC, as Managing Director in March 2012 and provides lead Equity Research coverage of the Biotechnology sector. Prior to Canaccord Genuity, Salveen was Managing Director covering Biotechnology at Collins Stewart LLC. Salveen joined Collins Stewart in May 2008 from Jefferies, where she was Senior Vice President and lead coverage Analyst on Biotechnology. Salveen received a B.S. in Biomedical and Electrical Engineering from Johns Hopkins University and is a Chartered Financial Analyst charter holder.

Mark Schoenebaum, MD
Senior Managing Director and Head, Healthcare Research, ISI Group

Mark Schoenebaum is a Senior Managing Director, heads ISI’s Health Care Research Team and is ISI’s Biotechnology & Pharmaceuticals-Major Analyst. He has been ranked Institutional Investor #1 Biotechnology analyst for the past 8 years. In 2012, his first year competing in the category, Mark was also ranked by Institutional Investor as a top 3 Pharmaceuticals/Major analyst. In addition, Mark has been highly ranked in the Greenwich Associates survey for several years.

Prior to joining ISI in 2010, Mark spent 2 years at Deutsche Bank as a Managing Director and Senior Biotechnology Analyst. Prior to that, Mark held a similar position at Bear Stearns.

Mark graduated from Indiana University with highest distinction in 1996 with a BA and received an MD from the Johns Hopkins University School of Medicine in 2000.

Joel Sendek
Managing Director, Stifel Nicolaus

Joel Sendek is a Managing Director and Biotechnology Analyst at Stifel, Nicolaus & Company. He is also Group Head of the Healthcare Equity Research at Stifel. He has been a senior biotechnology analyst for 15 years with coverage that spans both large-cap and small-cap companies. Prior to joining Stifel, Joel was a Managing Director and biotechnology analyst for 11 years at Lazard Capital Markets, where he established Lazard's healthcare equity research effort in 2000. Prior to Lazard he was a Senior Vice President and biotechnology research analyst at Gerard Klauer Mattison. He has been recognized by the Wall Street Journal as an All-Star Analyst with a #1 ranking for stock picking in biotechnology as well as first place in the "Home Run Hitter" category among all sectors. From 1992 to 1997, Joel served as Senior Director of Corporate Development at Progenics Pharmaceuticals, where he negotiated corporate partnerships, raised private equity capital and prepared the company for an IPO. Prior to Progenics, he worked in the corporate finance department at Goldman, Sachs & Co., focused on healthcare, from 1989 to 1992. Joel received a Bachelor of Arts in Biochemistry from Rice University.